Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.

Abstract

UNLABELLED Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide. Currently available drugs are not ideal due to high cost, toxicity, parenteral administration and suboptimal efficacy. Miltefosine is the only oral treatment (Impavido®) available to treat CL, given… (More)
DOI: 10.1111/jphp.12548

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.